Bluebird CEO defends $1.8 million price tag for gene therapy drug

Biotech and Pharma CEOs, doctors and investors have converged on MIT's campus in Cambridge for the first ever Stat Summit. Nick Leschly, CEO of Bluebird Bio, joins CNBC's Meg Tirrell to discuss the company's $1.8 million price tag for its new gene therapy to treat a rare genetic blood disorder.
Thu, Nov 21 201910:24 AM EST